首页> 外文期刊>Bone marrow transplantation >Matched unrelated bone marrow transplantation for combined immunodeficiency.
【24h】

Matched unrelated bone marrow transplantation for combined immunodeficiency.

机译:匹配的无关的骨髓移植治疗联合免疫缺陷。

获取原文
获取原文并翻译 | 示例
       

摘要

Bone marrow transplantation (BMT) from siblings is the treatment of choice for severe combined immunodeficiency (SCID). The objective of this study was to evaluate the efficiency of BMT from matched unrelated donors (MUD) in congenital immunodeficiencies when a sibling donor is unavailable. Sixteen consecutive patients with SCID (n = 9) and CID (n= 7), were referred for an unrelated donor search. Acceptable donors were found for all patients. Fifteen patients received busulfan and cyclophosphamide pretransplant conditioning. One patient had an early loss of graft and was reconditioned using cyclophosphamide and total body irradiation. The graft-versus-host disease (GVHD) prophylaxis used was methylprednisolone, cyclosporin A with or without methotrexate. Neutrophil engraftment was rapid and was achieved in all patients within a mean of 15.4 days. Only 13 episodes of fever were recorded shortly after BMT. GVHD of grade II or more was apparent in 2/9 (22%) of SCID patients and in 4/7 (57%) of CID patients. Overall survival was 75% with a mean follow-up of 47.4 months (range 18-101). Six out of nine SCID patients (67%) and 6/7 (86%) of CID patients are alive and well. Eleven patients had normal humoral immunity, and cell-mediated immunity as measured by flow cytometry and mitogenic responses, was intact in all patients. Intradermal candida skin test was positive in 9/10 patients tested. We conclude that BMT from MUD results in rapid engraftment and is therefore associated with a low rate of infection contributing to the improved survival rate. The protocol used is especially favorable for patients with combined immunodeficiency.
机译:兄弟姐妹的骨髓移植(BMT)是严重合并免疫缺陷病(SCID)的治疗选择。这项研究的目的是评估在没有同胞供者的情况下,来自匹配的无关供者(MUD)的BMT在先天性免疫缺陷中的有效性。连续十六名SCID(n = 9)和CID(n = 7)的患者被转介到无关的供体搜索中。找到了所有患者可接受的供体。 15名患者接受了白消安和环磷酰胺移植前调理。一名患者早期丢失了移植物,并使用环磷酰胺和全身照射进行了修复。预防移植物抗宿主病(GVHD)是甲基泼尼松龙,环孢菌素A(含或不含甲氨蝶呤)。中性粒细胞的植入很快,所有患者平均在15.4天内达到了中性粒细胞植入。 BMT后不久仅记录了13次发烧。 SCID患者的2/9(22%)和CID患者的4/7(57%)表现出II级或更高的GVHD。总生存率为75%,平均随访47.4个月(范围18-101)。在9名SCID患者中,有6名(67%)和6/7(86%)CID患者仍然健康。 11名患者的体液免疫力正常,并且通过流式细胞仪和有丝分裂反应测定的细胞介导的免疫力在所有患者中均完好无损。皮内念珠菌皮试验在9/10名患者中呈阳性。我们得出的结论是,来自MUD的BMT导致快速植入,因此与低感染率相关,有助于提高生存率。所使用的方案对合并免疫缺陷的患者特别有利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号